scholarly journals Protective Role of α-Calcitonin Gene-Related Peptide in Cardiovascular Diseases

2019 ◽  
Vol 10 ◽  
Author(s):  
Ambrish Kumar ◽  
Jay D. Potts ◽  
Donald J. DiPette
1998 ◽  
Vol 5 ◽  
pp. 50
Author(s):  
D.L. Shabituofu ◽  
X.H. Wang ◽  
N.K. Liu ◽  
S.Q. Peng ◽  
C.S. Tang ◽  
...  

Rheumatology ◽  
2020 ◽  
Author(s):  
Tazio Maleitzke ◽  
Alexander Hildebrandt ◽  
Jérôme Weber ◽  
Tamara Dietrich ◽  
Jessika Appelt ◽  
...  

Abstract Objectives Calcitonin gene-related peptide alpha (αCGRP) represents an immunomodulatory neuropeptide implicated in pain perception. αCGRP also functions as a critical regulator of bone formation and is overexpressed in patients with rheumatoid arthritis (RA). In the present study, we investigated the role of αCGRP in experimental RA regarding joint inflammation and bone remodelling. Methods Collagen II-antibody-induced arthritis (CAIA) was induced in wild type (WT) and αCGRP-deficient (αCGRP-/-) mice. Animals were monitored over 10 and 48 days with daily assessments of the semiquantitative arthritis score and grip strength test. Joint inflammation, cartilage degradation and bone erosions were assessed by histology, gene expression analysis and µCT. Results CAIA was accompanied by an overexpression of αCGRP in WT joints. αCGRP-/- mice displayed reduced arthritic inflammation and cartilage degradation. Congruently, the expression of TNF-α, IL-1β, CD80 and MMP13 was induced in WT, but not αCGRP-/- animals. WT mice displayed an increased bone turnover during the acute inflammatory phase, which was not the case in αCGRP-/- mice. Interestingly, WT mice displayed a full recovery from the inflammatory bone disease, whereas αCGRP-/- mice exhibited substantial bone loss over time. Conclusion This study demonstrates a proinflammatory and bone protective role of αCGRP in CAIA. Our data indicate that αCGRP not only enhances joint inflammation, but also controls bone remodelling as part of arthritis resolution. As novel αCGRP inhibitors are currently introduced clinically for the treatment of migraine, their potential impact on RA progression warrants further clinical investigation.


Endocrine ◽  
2017 ◽  
Vol 58 (1) ◽  
pp. 3-13 ◽  
Author(s):  
William Gustavo Lima ◽  
Gleuber Henrique Marques-Oliveira ◽  
Thaís Marques da Silva ◽  
Valéria Ernestânia Chaves

2006 ◽  
Vol 14 (25) ◽  
pp. 2484
Author(s):  
Fei-Fei Zhang ◽  
Jian-Zhong Mo ◽  
You-Ling Lv ◽  
Sheng-Liang Chen ◽  
Ming Lv ◽  
...  

2021 ◽  
Vol 8 ◽  
Author(s):  
Giuseppe Deganutti ◽  
Silvia Atanasio ◽  
Roxana-Maria Rujan ◽  
Patrick M. Sexton ◽  
Denise Wootten ◽  
...  

Class B1 G protein-coupled receptors (GPCRs) are important targets for many diseases, including cancer, diabetes, and heart disease. All the approved drugs for this receptor family are peptides that mimic the endogenous activating hormones. An understanding of how agonists bind and activate class B1 GPCRs is fundamental for the development of therapeutic small molecules. We combined supervised molecular dynamics (SuMD) and classic molecular dynamics (cMD) simulations to study the binding of the calcitonin gene-related peptide (CGRP) to the CGRP receptor (CGRPR). We also evaluated the association and dissociation of the antagonist telcagepant from the extracellular domain (ECD) of CGRPR and the water network perturbation upon binding. This study, which represents the first example of dynamic docking of a class B1 GPCR peptide, delivers insights on several aspects of ligand binding to CGRPR, expanding understanding of the role of the ECD and the receptor-activity modifying protein 1 (RAMP1) on agonist selectivity.


Sign in / Sign up

Export Citation Format

Share Document